Kris is Head of Biology at Grey Wolf Therapeutics where he leads the implementation of the preclinical and translational biology strategy for the different drug discovery programmes. He brings over 20 years of cell signalling expertise acquired at the interface of innovation between academia, the biotech and pharmaceutical sectors. His research in cell signalling pathways has been specifically applied to drug discovery in the fields of oncology and immunology.
During a distinguished career in academia, Kris was first to characterize several potent and selective chemical probes of kinases that are now widely used in the field. He also identified a new drug target which led academic drug discovery units as well as biotech companies to establish programmes, with one now undergoing PhII clinical trials. More recently, Kris crafted his art as Principal Scientist at Sygnature Discovery and Director of Kinase Biology at Exscientia where he led projects delivering 3 clinical candidates, all of which are currently being evaluated in clinical trials.
Kris holds a PhD in Medical Sciences from the Radboud University Nijmegen in the Netherlands and completed post-doctoral studies at the MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee in Scotland.